High-throughput screening of FDA-approved drugs using oxygen biosensor plates reveals secondary mitofunctional effects

Sunil Sahdeo, Alexey Tomilov, Kelly Komachi, Christine Iwahashi, Sandipan Datta, Owen Hughes, Paul J Hagerman, Gino A Cortopassi

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Repurposing of FDA-approved drugs with effects on mitochondrial function might shorten the critical path to mitochondrial disease drug development. We improved a biosensor-based assay of mitochondrial O2 consumption, and identified mitofunctional defects in cell models of LHON and FXTAS. Using this platform, we screened a 1600-compound library of clinically used drugs. The assay identified drugs known to affect mitochondrial function, such as metformin and decoquinate. We also identified several drugs not previously known to affect mitochondrial respiration including acarbose, metaraminol, gallamine triethiodide, and acamprosate. These previously unknown 'mitoactives' represent novel links to targets for mitochondrial regulation and potentially therapy, for mitochondrial disease.

Original languageEnglish (US)
Pages (from-to)116-125
Number of pages10
JournalMitochondrion
Volume17
DOIs
StatePublished - 2014

Fingerprint

Biosensing Techniques
Oxygen
Mitochondrial Diseases
Pharmaceutical Preparations
Decoquinate
Metaraminol
Gallamine Triethiodide
Acarbose
Critical Pathways
Metformin
Libraries
Respiration

Keywords

  • Bioenergetics
  • High-throughput screening
  • Mitochondrial disease
  • Oxygen

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology
  • Molecular Medicine

Cite this

High-throughput screening of FDA-approved drugs using oxygen biosensor plates reveals secondary mitofunctional effects. / Sahdeo, Sunil; Tomilov, Alexey; Komachi, Kelly; Iwahashi, Christine; Datta, Sandipan; Hughes, Owen; Hagerman, Paul J; Cortopassi, Gino A.

In: Mitochondrion, Vol. 17, 2014, p. 116-125.

Research output: Contribution to journalArticle

@article{6739147f17134256ba730846895780ed,
title = "High-throughput screening of FDA-approved drugs using oxygen biosensor plates reveals secondary mitofunctional effects",
abstract = "Repurposing of FDA-approved drugs with effects on mitochondrial function might shorten the critical path to mitochondrial disease drug development. We improved a biosensor-based assay of mitochondrial O2 consumption, and identified mitofunctional defects in cell models of LHON and FXTAS. Using this platform, we screened a 1600-compound library of clinically used drugs. The assay identified drugs known to affect mitochondrial function, such as metformin and decoquinate. We also identified several drugs not previously known to affect mitochondrial respiration including acarbose, metaraminol, gallamine triethiodide, and acamprosate. These previously unknown 'mitoactives' represent novel links to targets for mitochondrial regulation and potentially therapy, for mitochondrial disease.",
keywords = "Bioenergetics, High-throughput screening, Mitochondrial disease, Oxygen",
author = "Sunil Sahdeo and Alexey Tomilov and Kelly Komachi and Christine Iwahashi and Sandipan Datta and Owen Hughes and Hagerman, {Paul J} and Cortopassi, {Gino A}",
year = "2014",
doi = "10.1016/j.mito.2014.07.002",
language = "English (US)",
volume = "17",
pages = "116--125",
journal = "Mitochondrion",
issn = "1567-7249",
publisher = "Elsevier",

}

TY - JOUR

T1 - High-throughput screening of FDA-approved drugs using oxygen biosensor plates reveals secondary mitofunctional effects

AU - Sahdeo, Sunil

AU - Tomilov, Alexey

AU - Komachi, Kelly

AU - Iwahashi, Christine

AU - Datta, Sandipan

AU - Hughes, Owen

AU - Hagerman, Paul J

AU - Cortopassi, Gino A

PY - 2014

Y1 - 2014

N2 - Repurposing of FDA-approved drugs with effects on mitochondrial function might shorten the critical path to mitochondrial disease drug development. We improved a biosensor-based assay of mitochondrial O2 consumption, and identified mitofunctional defects in cell models of LHON and FXTAS. Using this platform, we screened a 1600-compound library of clinically used drugs. The assay identified drugs known to affect mitochondrial function, such as metformin and decoquinate. We also identified several drugs not previously known to affect mitochondrial respiration including acarbose, metaraminol, gallamine triethiodide, and acamprosate. These previously unknown 'mitoactives' represent novel links to targets for mitochondrial regulation and potentially therapy, for mitochondrial disease.

AB - Repurposing of FDA-approved drugs with effects on mitochondrial function might shorten the critical path to mitochondrial disease drug development. We improved a biosensor-based assay of mitochondrial O2 consumption, and identified mitofunctional defects in cell models of LHON and FXTAS. Using this platform, we screened a 1600-compound library of clinically used drugs. The assay identified drugs known to affect mitochondrial function, such as metformin and decoquinate. We also identified several drugs not previously known to affect mitochondrial respiration including acarbose, metaraminol, gallamine triethiodide, and acamprosate. These previously unknown 'mitoactives' represent novel links to targets for mitochondrial regulation and potentially therapy, for mitochondrial disease.

KW - Bioenergetics

KW - High-throughput screening

KW - Mitochondrial disease

KW - Oxygen

UR - http://www.scopus.com/inward/record.url?scp=84905378891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905378891&partnerID=8YFLogxK

U2 - 10.1016/j.mito.2014.07.002

DO - 10.1016/j.mito.2014.07.002

M3 - Article

C2 - 25034306

AN - SCOPUS:84905378891

VL - 17

SP - 116

EP - 125

JO - Mitochondrion

JF - Mitochondrion

SN - 1567-7249

ER -